MacroGenics said today it has regained full global rights to the Phase I cancer compound enoblituzumab (MGA271), after Servier opted not to exercise its option to develop and commercialize the B7-H3-targeting monoclonal antibody in Europe and other countries under a four-year-old collaboration.
That collaboration generated a $20 million upfront payment from Servier and could have resulted in up to $450 million for MacroGenics.